New targets for treatment against HCV infection

Best Practice and Research: Clinical Gastroenterology

Volumn 26, Issue 4, 2012, Pages 505-515

  Pan, Qiuwei ^a   Van Der Laan, Luc J W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

HCV entry; HCV genome; HCV replication; New therapeutic target

Indexed keywords

ANTIVIRUS AGENT; CYCLOSPORIN A; INTERFERON; ITX 5061; LADANEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 16 71; SERINE PROTEINASE INHIBITOR; TT 033; UNCLASSIFIED DRUG;

ARTICLE; DRUG TARGETING; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; VIRUS ENTRY; VIRUS GENOME; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CYCLOPHILINS; GENOME, VIRAL; HEPACIVIRUS; HEPATITIS C; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; VIRUS INTERNALIZATION; VIRUS PHYSIOLOGICAL PROCESSES; VIRUS REPLICATION;

EID: 84870414292     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2012.10.002     Document Type: Article

References (102)

1. Q.L. Choo, G. Kuo, A.J. Weiner, L.R. Overby, D.W. Bradley, and M. Houghton Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome Science 244 1989 359 362
2. A. Boonstra, L.J. van der Laan, T. Vanwolleghem, and H.L. Janssen Experimental models for hepatitis C viral infection Hepatology 50 2009 1646 1655
3. L.C. Casey, and W.M. Lee Hepatitis C therapy update Curr Opin Gastroenterol 28 2012 188 192
4. C.M. Rice New insights into HCV replication: potential antiviral targets Top Antivir Med 19 2011 117 120
5. H. Barth, C. Schafer, M.I. Adah, F. Zhang, R.J. Linhardt, and H. Toyoda Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate J Biological Chemistry 278 2003 41003 41012
6. V. Agnello, G. Abel, M. Elfahal, G.B. Knight, and Q.X. Zhang Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor Proc Natl Acad Sci U S A 96 1999 12766 12771
7. E. Scarselli, H. Ansuini, R. Cerino, R.M. Roccasecca, S. Acali, and G. Filocamo The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus EMBO J 21 2002 5017 5025
8. S. Levy, S.C. Todd, and H.T. Maecker CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system Annu Rev Immunol 16 1998 89 109
9. M.J. Evans, T. von Hahn, D.M. Tscherne, A.J. Syder, M. Panis, and B. Wolk Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry Nature 446 2007 801 805
10. A. Ploss, M.J. Evans, V.A. Gaysinskaya, M. Panis, H. You, and Y.P. de Jong Human occludin is a hepatitis C virus entry factor required for infection of mouse cells Nature 2009
11. J. Lupberger, M.B. Zeisel, F. Xiao, C. Thumann, I. Fofana, and L. Zona EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy Nat Med 17 2011 589 595
12. B. Sainz Jr., N. Barretto, D.N. Martin, N. Hiraga, M. Imamura, and S. Hussain Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor Nat Med 18 2012 281 285
13. N. Yilmaz, M.L. Shiffman, R.T. Stravitz, R.K. Sterling, V.A. Luketic, and A.J. Sanyal A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation Liver Transpl 13 2007 975 983
14. D. Samuel, T. Bizollon, C. Feray, B. Roche, S.N. Ahmed, and C. Lemonnier Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study Gastroenterology 124 2003 642 650
15. L. Mensa, G. Crespo, M.J. Gastinger, J. Kabat, S. Perez-del-Pulgar, and R. Miquel Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics Hepatology 53 2011 1436 1445
16. M.B. Zeisel, I. Fofana, S. Fafi-Kremer, and T.F. Baumert Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies J Hepatol 54 2011 566 576
17. A.G. Angus, and A.H. Patel Immunotherapeutic potential of neutralizing antibodies targeting conserved regions of the HCV envelope glycoprotein E2 Future Microbiol 6 2011 279 294
18. G.L. Davis, D.R. Nelson, N. Terrault, T.L. Pruett, T.D. Schiano, and C.V. Fletcher A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients Liver Transpl 11 2005 941 949
19. T.D. Schiano, M. Charlton, Z. Younossi, E. Galun, T. Pruett, and R. Tur-Kaspa Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study Liver Transpl 12 2006 1381 1389
20. M. Law, T. Maruyama, J. Lewis, E. Giang, A.W. Tarr, and Z. Stamataki Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge Nat Med 14 2008 25 27
21. E. Giang, M. Dorner, J.C. Prentoe, M. Dreux, M.J. Evans, and J. Bukh Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus Proc Natl Acad Sci U S A 109 2012 6205 6210
22. Z.Y. Keck, J. Xia, Y. Wang, W. Wang, T. Krey, and J. Prentoe Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate PLoS Pathog 8 2012 e1002653
23. M.B. Zeisel, G. Koutsoudakis, E.K. Schnober, A. Haberstroh, H.E. Blum, and F.L. Cosset Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81 Hepatology 46 2007 1722 1731
24. P. Meuleman, M.T. Catanese, L. Verhoye, I. Desombere, A. Farhoudi, and C.T. Jones A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo Hepatology 55 2012 364 372
25. M.J. Farquhar, H.J. Harris, and J.A. McKeating Hepatitis C virus entry and the tetraspanin CD81 Biochem Soc Trans 39 2011 532 536
26. P. Pileri, Y. Uematsu, S. Campagnoli, G. Galli, F. Falugi, and R. Petracca Binding of hepatitis C virus to CD81 Science 282 1998 938 941
27. S. Molina, V. Castet, L. Pichard-Garcia, C. Wychowski, E. Meurs, and J.M. Pascussi Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent J Virol 82 2008 569 574
28. Q. Pan, S.D. Henry, H.J. Metselaar, B. Scholte, J. Kwekkeboom, and H.W. Tilanus Combined antiviral activity of interferon-alpha and RNA interference directed against hepatitis C without affecting vector delivery and gene silencing J Mol Med (Berl) 87 2009 713 722
29. P. Meuleman, J. Hesselgesser, M. Paulson, T. Vanwolleghem, I. Desombere, and H. Reiser Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo Hepatology 48 2008 1761 1768
30. I. Fofana, S.E. Krieger, F. Grunert, S. Glauben, F. Xiao, and S. Fafi-Kremer Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes Gastroenterology 139 2010 953 964 64 e1-4
31. A.J. Syder, H. Lee, M.B. Zeisel, J. Grove, E. Soulier, and J. Macdonald Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors J Hepatol 54 2011 48 55
32. D. Masson, M. Koseki, M. Ishibashi, C.J. Larson, S.G. Miller, and B.D. King Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor Arterioscler Thromb Vasc Biol 29 2009 2054 2060
33. F. Wong-Staal, A.J. Syder, and J.F. McKelvy Targeting HCV entry for development of therapeutics Viruses 2 2010 1718 1733
34. G.A. Coburn, D.N. Fisch, S.M. Moorji, J.M. de Muys, J.D. Murga, and D. Paul Novel small-molecule inhibitors of hepatitis C virus entry block viral spread and promote viral clearance in cell culture PLoS One 7 2012 e35351
35. S. Haid, A. Novodomska, J. Gentzsch, C. Grethe, S. Geuenich, and D. Bankwitz A plant-derived flavonoid inhibits entry of all HCV genotypes into human hepatocytes Gastroenterology 143 2012 213 222 e5
36. F. Penin, J. Dubuisson, F.A. Rey, D. Moradpour, and J.M. Pawlotsky Structural biology of hepatitis C virus Hepatology 39 2004 5 19
37. R. Bartenschlager, L. Ahlborn-Laake, J. Mous, and H. Jacobsen Kinetic and structural analyses of hepatitis C virus polyprotein processing J Virol 68 1994 5045 5055
38. V. Lohmann, F. Korner, J. Koch, U. Herian, L. Theilmann, and R. Bartenschlager Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line Science 285 1999 110 113
39. S.E. Behrens, L. Tomei, and R. De Francesco Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus EMBO J 15 1996 12 22
40. K. Moriishi, and Y. Matsuura Exploitation of lipid components by viral and host proteins for hepatitis C virus infection Front Microbiol 3 2012 54
41. Y. Miyanari, K. Atsuzawa, N. Usuda, K. Watashi, T. Hishiki, and M. Zayas The lipid droplet is an important organelle for hepatitis C virus production Nat Cell Biol 9 2007 1089 1097
42. M. Ait-Goughoulte, T. Kanda, K. Meyer, J.S. Ryerse, R.B. Ray, and R. Ray Hepatitis C virus genotype 1a growth and induction of autophagy J Virol 82 2008 2241 2249
43. P.Y. Ke, and S.S. Chen Activation of the unfolded protein response and autophagy after hepatitis C virus infection suppresses innate antiviral immunity in vitro J Clin Invest 121 2011 37 56
44. S. Shrivastava, A. Raychoudhuri, R. Steele, R. Ray, and R.B. Ray Knockdown of autophagy enhances the innate immune response in hepatitis C virus-infected hepatocytes Hepatology 53 2011 406 414
45. M. Nakagawa, N. Sakamoto, Y. Tanabe, T. Koyama, Y. Itsui, and Y. Takeda Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins Gastroenterology 129 2005 1031 1041
46. K. Watashi, N. Ishii, M. Hijikata, D. Inoue, T. Murata, and Y. Miyanari Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase Mol Cell 19 2005 111 122
47. F. Fernandes, D.S. Poole, S. Hoover, R. Middleton, A.C. Andrei, and J. Gerstner Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B Hepatology 46 2007 1026 1033
48. S. Ciesek, E. Steinmann, H. Wedemeyer, M.P. Manns, J. Neyts, and N. Tautz Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A Hepatology 50 2009 1638 1645
49. H. Tu, L. Gao, S.T. Shi, D.R. Taylor, T. Yang, and A.K. Mircheff Hepatitis C virus RNA polymerase and NS5A complex with a SNARE-like protein Virology 263 1999 30 41
50. L. Gao, H. Aizaki, J.W. He, and M.M. Lai Interactions between viral nonstructural proteins and host protein hVAP-33 mediate the formation of hepatitis C virus RNA replication complex on lipid raft J Virol 78 2004 3480 3488
51. P.Y. Goh, Y.J. Tan, S.P. Lim, Y.H. Tan, S.G. Lim, and F. Fuller-Pace Cellular RNA helicase p68 relocalization and interaction with the hepatitis C virus (HCV) NS5B protein and the potential role of p68 in HCV RNA replication J Virol 78 2004 5288 5298
52. Z. Yi, C. Fang, T. Pan, J. Wang, P. Yang, and Z. Yuan Subproteomic study of hepatitis C virus replicon reveals Ras-GTPase-activating protein binding protein 1 as potential HCV RC component Biochem Biophys Res Commun 350 2006 174 178
53. H. Aizaki, K.S. Choi, M. Liu, Y.J. Li, and M.M. Lai Polypyrimidine-tract- binding protein is a component of the HCV RNA replication complex and necessary for RNA synthesis J Biomed Sci 13 2006 469 480
54. G. Randall, M. Panis, J.D. Cooper, T.L. Tellinghuisen, K.E. Sukhodolets, and S. Pfeffer Cellular cofactors affecting hepatitis C virus infection and replication Proc Natl Acad Sci U S A 104 2007 12884 12889
55. Y. Wang, N. Kato, A. Jazag, N. Dharel, M. Otsuka, and H. Taniguchi Hepatitis C virus core protein is a potent inhibitor of RNA silencing-based antiviral response Gastroenterology 130 2006 883 892
56. T.I. Ng, H. Mo, T. Pilot-Matias, Y. He, G. Koev, and P. Krishnan Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology Hepatology 45 2007 1413 1421
57. L. Supekova, F. Supek, J. Lee, S. Chen, N. Gray, and J.P. Pezacki Identification of human kinases involved in hepatitis C virus replication by small interference RNA library screening J Biological Chemistry 283 2008 29 36
58. L. He, and G.J. Hannon MicroRNAs: small RNAs with a big role in gene regulation Nat Rev Genet 5 2004 522 531
59. M. Lagos-Quintana, R. Rauhut, A. Yalcin, J. Meyer, W. Lendeckel, and T. Tuschl Identification of tissue-specific microRNAs from mouse Curr Biol 12 2002 735 739
60. C.L. Jopling, M. Yi, A.M. Lancaster, S.M. Lemon, and P. Sarnow Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA Science 309 2005 1577 1581
61. R.K. Jangra, M. Yi, and S.M. Lemon Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122 J Virol 84 2010 6615 6625
62. G.J. Towers The control of viral infection by tripartite motif proteins and cyclophilin A Retrovirology 4 2007 40
63. A.H. de Wilde, J.C. Zevenhoven-Dobbe, Y. van der Meer, V. Thiel, K. Narayanan, and S. Makino Cyclosporin A inhibits the replication of diverse coronaviruses J Gen Virol 92 2011 2542 2548
64. K. Watashi, M. Hijikata, M. Hosaka, M. Yamaji, and K. Shimotohno Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes Hepatology 38 2003 1282 1288
65. T.L. Foster, P. Gallay, N.J. Stonehouse, and M. Harris Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner J Virol 85 2011 7460 7464
66. Q. Pan, H.J. Metselaar, P. de Ruiter, J. Kwekkeboom, H.W. Tilanus, and H.L. Janssen Calcineurin inhibitor tacrolimus does not interfere with the suppression of hepatitis C virus infection by interferon-alpha Liver Transpl 16 2010 520 526
67. R.J. Firpi, C. Soldevila-Pico, G.G. Morelli, R. Cabrera, C. Levy, and V.C. Clark The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study Dig Dis Sci 55 2010 196 203
68. Q. Pan, H.W. Tilanus, H.J. Metselaar, H.L. Janssen, and L.J. van der Laan Virus-drug interactions-molecular insight into immunosuppression and HCV Nat Rev Gastroenterol Hepatol 9 2012 355 362
69. P.A. Gallay Cyclophilin inhibitors Clin Liver Dis 13 2009 403 417
70. R. Flisiak, A. Horban, P. Gallay, M. Bobardt, S. Selvarajah, and A. Wiercinska-Drapalo The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus Hepatology 47 2008 817 826
71. R. Flisiak, S.V. Feinman, M. Jablkowski, A. Horban, W. Kryczka, and M. Pawlowska The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients Hepatology 49 2009 1460 1468
72. R. Flisiak, J. Jaroszewicz, I. Flisiak, and T. Lapinski Update on alisporivir in treatment of viral hepatitis C Expert Opin Investig Drugs 21 2012 375 382
73. C.L. Jopling, S. Schutz, and P. Sarnow Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome Cell Host Microbe 4 2008 77 85
74. C. Jopling Liver-specific microRNA-122: biogenesis and function RNA Biol 9 2012 137 142
75. G. Hutvagner, M.J. Simard, C.C. Mello, and P.D. Zamore Sequence-specific inhibition of small RNA function PLoS Biol 2 2004 E98
76. J. Krutzfeldt, N. Rajewsky, R. Braich, K.G. Rajeev, T. Tuschl, and M. Manoharan Silencing of microRNAs in vivo with 'antagomirs' Nature 438 2005 685 689
77. Y. Shan, J. Zheng, R.W. Lambrecht, and H.L. Bonkovsky Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes Gastroenterology 133 2007 1166 1174
78. C. Esau, S. Davis, S.F. Murray, X.X. Yu, S.K. Pandey, and M. Pear miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting Cell Metab 3 2006 87 98
79. A. Valoczi, C. Hornyik, N. Varga, J. Burgyan, S. Kauppinen, and Z. Havelda Sensitive and specific detection of microRNAs by northern blot analysis using LNA-modified oligonucleotide probes Nucleic Acids Res 32 2004 e175
80. J. Elmen, M. Lindow, S. Schutz, M. Lawrence, A. Petri, and S. Obad LNA-mediated microRNA silencing in non-human primates Nature 452 2008 896 899
81. R.E. Lanford, E.S. Hildebrandt-Eriksen, A. Petri, R. Persson, M. Lindow, and M.E. Munk Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection Science 327 2010 198 201
82. H.L. Janssen, H.W. Reesink, S. Zeuzem, E. Lawitz, M. Rodriguez-Torres, and A. Chen A randomized, double-blind, placebo (Plb) controlled safety and anti-viral proof of concept study of Miravirsen (Mir), an oligonucleotide targeting Mir-122, in treatment naive patients with genotype 1 (Gt1) chronic Hcv infection Hepatology 54 2011 1430a-a
83. P. Simmonds, J. Bukh, C. Combet, G. Deleage, N. Enomoto, and S. Feinstone Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes Hepatology 42 2005 962 973
84. R. Prabhu, R.F. Garry, and S. Dash Small interfering RNA targeted to stem-loop II of the 5′ untranslated region effectively inhibits expression of six HCV genotypes Virol J 3 2006 100
85. A. Fire, S. Xu, M.K. Montgomery, S.A. Kostas, S.E. Driver, and C.C. Mello Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans Nature 391 1998 806 811
86. K. Chang, S.J. Elledge, and G.J. Hannon Lessons from nature: microRNA-based shRNA libraries Nat Methods 3 2006 707 714
87. G.J. Hannon RNA interference Nature 418 2002 244 251
88. S.B. Kapadia, A. Brideau-Andersen, and F.V. Chisari Interference of hepatitis C virus RNA replication by short interfering RNAs Proc Natl Acad Sci U S A 100 2003 2014 2018
89. Q. Pan, H.W. Tilanus, H.L. Janssen, and L.J. van der Laan Prospects of RNAi and microRNA-based therapies for hepatitis C Expert Opin Biol Ther 9 2009 713 724
90. J.A. Wilson, S. Jayasena, A. Khvorova, S. Sabatinos, I.G. Rodrigue-Gervais, and S. Arya RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells Proc Natl Acad Sci U S A 100 2003 2783 2788
91. S.D. Henry, P. van der Wegen, H.J. Metselaar, H.W. Tilanus, B.J. Scholte, and L.J. van der Laan Simultaneous targeting of HCV replication and viral binding with a single lentiviral vector containing multiple RNA interference expression cassettes Mol Ther 14 2006 485 493
92. S. Khaliq, S. Jahan, A. Pervaiz, U. Ali Ashfaq, and S. Hassan Down-regulation of IRES containing 5′UTR of HCV genotype 3a using siRNAs Virol J 8 2011 221
93. D.A. Suhy, S.C. Kao, T. Mao, L. Whiteley, H. Denise, and B. Souberbielle Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate model Mol Ther 2012
94. H. Lee, A.K. Lytton-Jean, Y. Chen, K.T. Love, A.I. Park, and E.D. Karagiannis Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery Nat Nanotechnol 7 2012 389 393
95. P.K. Chandra, A.K. Kundu, S. Hazari, S. Chandra, L. Bao, and T. Ooms Inhibition of hepatitis C virus replication by intracellular delivery of multiple siRNAs by nanosomes Mol Ther 20 2012 1724 1736
96. Q.W. Pan, R. Cai, X.Y. Liu, and C. Qian A novel strategy for cancer gene therapy: RNAi Chin Sci Bull 51 2006 1145 1151
97. L.J. van der Laan, Y. Wang, H.W. Tilanus, H.L. Janssen, and Q. Pan AAV-mediated gene therapy for liver diseases: the prime candidate for clinical application? Expert Opin Biol Ther 11 2011 315 327
98. Q. Pan, P.E. de Ruiter, K.J. von Eije, R. Smits, J. Kwekkeboom, and H.W. Tilanus Disturbance of the microRNA pathway by commonly used lentiviral shRNA libraries limits the application for screening host factors involved in hepatitis C virus infection FEBS Lett 585 2011 1025 1030
99. D. Grimm, K.L. Streetz, C.L. Jopling, T.A. Storm, K. Pandey, and C.R. Davis Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways Nature 441 2006 537 541
100. D. Grimm, L. Wang, J.S. Lee, N. Schurmann, S. Gu, and K. Borner Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver J Clin Invest 120 2010 3106 3119
101. Q.W. Pan, S.D. Henry, B.J. Scholte, H.W. Tilanus, H.L. Janssen, and L.J. van der Laan New therapeutic opportunities for hepatitis C based on small RNA World J Gastroenterol 13 2007 4431 4436
102. S.H. Hsu, B. Wang, J. Kota, J. Yu, S. Costinean, and H. Kutay Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver J Clin Invest 122 2012 2871 2883